Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

385results about How to "Improving immunogenicity" patented technology

Porcine epidemic diarrhea virus S protein mutant, nucleic acid molecule, subunit vaccine and application

The invention provides a porcine epidemic diarrhea virus S protein mutant, a nucleic acid molecule, a subunit vaccine and application. Compared with wild type porcine epidemic diarrhea virus S protein, the porcine epidemic diarrhea virus S protein mutant has the advantage that amino acid at the 1076th site, amino acid at the 1077th site, amino acid at the 1016th site and amino acid at the 1017th site are mutated into proline. The natural trimer which is stable and maintains the conformation of the S protein before fusion is constructed, the safe and efficient PEDV subunit vaccine is obtained, and the use effect and immunogenicity of the porcine epidemic diarrhea vaccine can be improved; moreover, compared with a wild type S protein, the porcine epidemic diarrhea virus S protein mutant disclosed by the invention has a higher expression quantity.
Owner:湖南派智生物科技有限公司

Brucella recombinant multivalent epitope vaccine

PendingCN119015404Aavoid decompositionprecise targetingBacterial antigen ingredientsAntibacterial agentsAnaphylaxisHuman brucellosis
The invention belongs to the technical field of biomedicine, and particularly discloses a Brucella recombinant multivalent epitope vaccine which comprises IgVCTLA-4, a connected CD8 < + > T cell epitope, a connected CD4 < + > T cell epitope, a connected linear B cell epitope and a connected conformation B cell epitope. The protein of the vaccine provided by the invention is stable, hydrophilic and soluble, does not have anaphylaxis, has good immunogenicity, is expected to activate an organism to generate an effective immune response against brucella infection, blocks infection between livestock and people, realizes effective prevention and control of human brucellosis, and has good application prospects. The method can be a powerful method for preventing the occurrence and development of brucellosis in the future.
Owner:FIRST AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIVERSITY

RSV F protein mutant as well as preparation method and application thereof

PendingCN119019510AImproving immunogenicityStrong immunity inducing effectDepsipeptidesAntiviralsRespiratory syncytial virus antibodyF protein
The invention belongs to the technical field of biological medicine, and particularly relates to an RSV F protein mutant, a preparation method thereof and application of the RSV F protein mutant in preparation of a respiratory syncytial virus vaccine. The protein mutant is provided in a combined mutation form on the premise of not modifying the natural furin cleavage site and pep27 of the wild RSV F protein. The F protein mutant disclosed by the invention is high in expression quantity and good in stability, and can be used for preparing products such as vaccines, respiratory syncytial virus antibodies, anti-respiratory syncytial virus serum and diagnostic antigens.
Owner:JIANGSU RECBIO TECH CO LTD +1

Respiratory syncytial virus antigenic polypeptides, nucleic acids and vaccines

The invention provides a respiratory syncytial virus antigenic polypeptide, nucleic acid and a vaccine. Compared with the respiratory syncytial virus wild type Pre-F protein, the respiratory syncytial virus antigenic polypeptide or the immunogenic fragment of the respiratory syncytial virus antigenic polypeptide has the following changes: the 104th to 144th regions of the Pre-F protein are replaced with GS linker; two groups of disulfide bonds are introduced into S155C, S290C, A149C and Y458C; the S190F and the V207L are used for realizing cavity filling; and P102A, L373R, I379V, M447V, P102A, L373R, the C terminal of the respiratory syncytial virus antigenic polypeptide or the immunogenic fragment thereof comprises a cytoplasm tail region fragment, and the cytoplasm tail region fragment is a fragment derived from 3-10 continuous amino acid residues of a PreF protein cytoplasm tail region. According to the present invention, the pre-F immunogenicity and / or stability can be improved, and the protein expression level can be easily improved.
Owner:SHENZHEN RHEGEN BIOTECHNOLOGY CO LTD +1

Recombinant fusion protein of respiratory syncytial virus of prefusion conformation and preparation method and application of recombinant fusion protein

The present invention relates to a respiratory syncytial virus subtype B (RSV-B) recombinant F protein, a polynucleotide encoding the same, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a host cell wherein the polynucleotide, the nucleic acid construct or the expression vector is transformed or transfected, a stabilized trimer formed therefrom, and a method for preparing the same. An immunogenic composition comprising any of the foregoing, and its use in the preparation of a vaccine for the prevention and / or treatment of respiratory syncytial virus infection. The RSV-B recombinant F protein comprises at least one specific epitope of the pre-fusion F protein, a stable F protein tripolymer with pre-fusion conformation can be formed, the expression is stable, the form is uniform, and the yield is greatly improved; the formed F protein trimer has good immunogenicity, can stimulate an organism to generate high-level antibody titer, and has great significance in clinical treatment and prevention and control of the respiratory syncytial virus.
Owner:BEIJING BENEWILL TECH DEV CO LTD

Monkey pox mRNA immunogen composition capable of rapidly and efficiently enhancing immune response and application of monkey pox mRNA immunogen composition

The invention provides a monkey pox mRNA immunogen composition capable of rapidly and efficiently enhancing immune response and application of the monkey pox mRNA immunogen composition. The composition comprises at least one antigen peptide or structural protein and an immune enhancement factor IL-15. The composition is used for preparing a monkey pox mRNA vaccine capable of efficiently enhancing immune response, and compared with an mRNA vaccine independently coding a corresponding antigen, the composition can induce a high-level neutralizing antibody against monkey pox virus or vaccinia virus with high homology of the monkey pox virus after being inoculated for one time, and can stimulate relatively strong T cell response; 100% immune protection is provided for lethal attack of monkey pox virus and vaccinia virus; when the vaccine is prepared, compared with a mixed single immunogen, a plurality of epitopes of MPXV can be simultaneously coded from one mRNA molecule, and independent expression and non-interference among the immunogens can be realized, so that effective prevention and / or treatment on orthopox viruses such as monkey pox virus and / or vaccinia virus can be realized, and the vaccine has a relatively high clinical application prospect.
Owner:THE THIRD PEOPLES HOSPITAL OF SHENZHEN

Nucleic acid aptamer-based covalent lysosome targeting chimera and application thereof in protein degradation and immunotherapy

The invention discloses a covalent lysosome targeting chimera based on a nucleic acid aptamer and application of the covalent lysosome targeting chimera in protein degradation and immunotherapy, and belongs to the technical field of biology. The invention designs a covalent lysosome targeting chimera with click chemical reaction activity, and the simple and efficient covalent lysosome targeting chimera is used for realizing efficient protein degradation at the levels of cells and living bodies. When the tool is used for targeted degradation of immunotherapy biomarkers, immunogenic apoptosis of tumor cells can be caused, so that killing of an immune system to tumors is more efficiently activated. Meanwhile, the covalent lysosome targeting chimera overcomes the problem of immune-related side effects confronted by existing antibodies and polysaccharide peptide drugs, and can effectively avoid the potential occurrence risk of the immune-related side effects while efficiently degrading the target protein.
Owner:刘庄

Chimeric PEDV infectious clone plasmid, PEDV chimeric virus and construction method and application thereof

The invention discloses a chimeric PEDV (porcine epidemic diarrhea virus) infectious clone plasmid, a PEDV chimeric virus as well as a construction method and application thereof. According to the invention, a PEDV genome is used as a skeleton for the first time, the chimeric virus for expressing the extracellular domain of the TGEV S protein is successfully rescued, and it is found that the TCID50 of the chimeric virus for expressing the extracellular domain of the TGEV S protein can be increased by 6.2 times compared with that of the chimeric PEDV for expressing the TGEV S protein. The recombinant virus is used as an inactivated vaccine for immunizing mice, so that the immunogenicity of TGEV S protein can be greatly improved, a body is stimulated to generate a higher-level neutralizing antibody aiming at TGEV, and the titer of the neutralizing antibody aiming at TGEV is improved by 16.8 times. Therefore, more possibilities are provided for modification of viral genomes, a novel method for improving immunogenicity of the TGEV inactivated vaccine is invented, and a basis is provided for research and development of the TGEV vaccine.
Owner:YANGZHOU UNIV

Mycoplasma hyopneumoniae multi-antigen fusion protein and vaccine composition and application thereof

The invention discloses a mycoplasma hyopneumoniae multi-antigen fusion protein and a vaccine composition and application thereof, and belongs to the technical field of genetic engineering and vaccines. The fusion protein comprises an escherichia coli heat-labile enterotoxin LTB, a mycoplasma hyopneumoniae antigen protein P97R1, a mycoplasma hyopneumoniae lipoprotein 418 and a mycoplasma hyopneumoniae surface antigen protein P46 from the N terminal to the C terminal in the sequence. The vaccine composition comprises the fusion protein and an adjuvant acceptable in veterinary medicine. A vaccine prepared from the fusion protein has the advantages of higher pertinence and immunogenicity, the cell and humoral immune response level is remarkably improved, and meanwhile, the fusion protein is easy to purify and prepare and suitable for large-scale industrial production.
Owner:INST OF ANIMAL SCI & VETERINARY HUBEI ACADEMY OF AGRI SCI

Novel coronavirus SARS-CoV-2 mutant vaccine and application

The invention relates to a novel coronavirus SARS-CoV-2 mutant vaccine and application, the vaccine comprises a fusion protein, and the fusion protein comprises: (1) interferon or a functional fragment thereof; (2) a novel coronavirus SARS-CoV-2Omicron mutant strain S protein or a functional fragment of the novel coronavirus SARS-CoV-2Omicron mutant strain S protein; and (3) an immunoglobulin Fc region. Molecule and process optimization of the fusion protein comprises improvement of process developability and immunogenicity, and the vaccine can improve immunogenicity and antibody titer of a mutant new crown antigen through convergence mutation design, efficiently generate a neutralizing antibody, significantly improve defense ability to a variant strain, and can be massively and industrially produced.
Owner:LIVZON MABPHARM

Preparation method and application of porcine pseudorabies virus multi-epitope polypeptide

The invention discloses a preparation method and application of porcine pseudorabies virus multi-epitope polypeptide, and belongs to the technical field of veterinary biological products. The multi-epitope polypeptide comprises a cytotoxic T cell epitope, a helper T cell epitope and a linear B cell epitope; the cell epitopes are screened from key immunogenic proteins of the pseudorabies virus by using an immunoinformatics method. The porcine pseudorabies virus multi-epitope polypeptide designed by the invention is high in safety, has better antigenicity and physicochemical properties, can be efficiently expressed, and can be recognized by a pseudorabies virus specific antibody. By applying the porcine pseudorabies virus multi-epitope polypeptide, high-level specific antibodies and cellular immune response can be continuously induced to generate, strong protective efficacy is generated, and mice can be protected from death when infected with a lethal dose of porcine pseudorabies virus. Therefore, the multi-epitope polypeptide disclosed by the invention can be used as an alternative antigen of a porcine pseudorabies virus vaccine, the use of active virus is avoided, and a tool is provided for eradication of porcine pseudorabies virus.
Owner:HUAZHONG AGRI UNIV +1

Porcine rotavirus nanoparticles as well as preparation method and application thereof

The invention belongs to the technical field of veterinary vaccines, and particularly relates to porcine rotavirus nanoparticles as well as a preparation method and application thereof. The invention provides a porcine rotavirus nano-particle. The porcine rotavirus nano-particle comprises a porcine rotavirus VP8 protein fragment, a dioxo tetrahydropteridine synthase and a linker, wherein the linker comprises a porcine rotavirus VP8 protein fragment and a dioxo tetrahydropteridine synthase; the porcine rotavirus VP8 protein fragment is connected with the dioxo tetrahydropteridine synthase through the linker, and the linker is connected with the dioxo tetrahydropteridine synthase; the amino acid sequence of the porcine rotavirus VP8 protein fragment is as shown in SEQ ID NO. 1. The porcine rotavirus nanoparticles can display more antigens at a time, so that the immunogenicity of vaccines is improved, and animals can be induced to generate higher antibody level. Results of the embodiment show that the prepared porcine rotavirus nanoparticle vaccine can cause a higher specific antibody level, and compared with a porcine rotavirus VP8 protein fragment monomer immune group, the porcine rotavirus nanoparticle vaccine can cause a higher neutralizing antibody level.
Owner:HUAZHONG AGRI UNIV

Chicken infectious anemia virus, chicken infectious anemia virus egg yolk antibody and preparation method and application thereof

The invention relates to the technical field of bioengineering, and particularly discloses a chicken infectious anemia virus, a chicken infectious anemia virus egg yolk antibody and a preparation method and application thereof. The invention relates to a chicken infectious anemia virus, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and is named as the chicken infectious anemia virus RD240101A, the preservation date is September 23, 2024, and the preservation number is CGMCC NO.46198. The chicken infectious anemia virus has the advantages that the chicken infectious anemia virus is named as the chicken infectious anemia virus RD240101A; the chicken infectious anemia virus egg yolk antibody is prepared by taking an inactivated vaccine prepared from the chicken infectious anemia virus RD240101A as an immunogen, is high in specificity and good in safety, does not have any local or whole-body adverse reaction caused by injection of the antibody after being inoculated to chicks, can provide effective immune protection for chicken flocks, and can be used for preparing the chicken infectious anemia virus egg yolk antibody. And the method has a good commercial development prospect.
Owner:QINGDAO RUNDA BIOTECH

Acinetobacter baumannii outer membrane protein liposome vaccine as well as preparation method and application thereof

The invention discloses an acinetobacter baumannii outer membrane protein liposome vaccine as well as a preparation method and application thereof, and relates to the field of biological medicines. The acinetobacter baumannii outer membrane protein liposome vaccine is obtained by efficiently expressing the acinetobacter baumannii outer membrane protein through a genetic engineering means and combining the obtained multiple outer membrane proteins as antigens with a lipid mixture and an adjuvant, and the acinetobacter baumannii outer membrane protein liposome vaccine is proved to be capable of providing complete protection for mice challenged by lethal dose acinetobacter baumannii. Wherein the outer membrane protein loaded by the lipidosome realizes structural refolding, the protein immunogenicity is enhanced, and the lipidosome can reduce the toxicity of the outer membrane protein; omp38 + BauA + FimA may be an effective antigen combination for preventing acinetobacter baumannii infection; as a TLR2 agonist, Pam2CSK4 has a strong auxiliary effect on an acinetobacter baumannii liposome vaccine, can induce innate immune response activation, and provides a more comprehensive protection effect on a host.
Owner:ARMY MEDICAL UNIV

Method for screening potential neoantigen of tumor from transposition element

The invention provides a method for screening a potential neoantigen of a tumor from a transposon element. The method comprises the following steps: collecting tumor tissue transcriptome sequencing data and normal tissue transcriptome sequencing data; identifying a TE transcript new type TEtrans based on a TE splicing event; performing feature analysis on the TEtrans; the TEtrans with the potential coding capability is screened out; and identifying the new antigen epitope peptide from the TEtrans: hydrolyzing all open reading frames of the to-be-selected TEtrans into 9 peptides which are mutually overlapped, removing annotated peptide fragments contained in Uniprot, defining the new antigen epitope peptide from the TEtrans according to allele typing of a tumor sample, further comparing the new antigen from the TEtrans with three common new antigens from genomic variation sources, and identifying the new antigen from the TEtrans. And screening to obtain the tumor potential new antigen. According to the invention, a brand new intergene region TE source transcript is successfully identified, and the transcript can be uniquely positioned and accurately quantified, so that a tumor specific transcript is screened as a potential tumor new antigen, and the method has huge potential in the aspect of developing tumor new antigen vaccines, especially tumors with low mutation load.
Owner:FUDAN UNIV SHANGHAI CANCER CENT

Application of polypeptide DGEA or derivative thereof in promoting differentiation of pluripotent stem cells into mesenchymal stem cells

The invention belongs to the technical field of stem cell development and differentiation, and discloses application of polypeptide DGEA or a derivative thereof in promoting pluripotent stem cells to be differentiated into mesenchymal stem cells. The invention specifically discloses application of the polypeptide and the derivative thereof in promoting differentiation of pluripotent stem cells into pluripotent stem cells or preparing products for promoting differentiation of pluripotent stem cells into pluripotent stem cells. The amino acid sequence of the polypeptide is DGEA. The invention discloses the application of DGEA in promoting differentiation of pluripotent stem cells (embryonic stem cells, embryonic germ cells or induced pluripotent stem cells) into pluripotent stem cells (mesenchymal stem cells) for the first time, and the effect of DGEA is verified through corresponding experiments. The DGEA can obviously improve the efficiency of differentiating the embryonic stem cells, the embryonic germ cells or the induced pluripotent stem cells into the mesenchymal stem cells, and the obtained mesenchymal stem cells are high in safety and high in differentiation capacity.
Owner:FUTURE HOMO SAPIENS INST OF REGENERATIVE MEDICINE CO LTD (FHSR) +1

Chicken infectious laryngotracheitis subunit vaccine and application thereof

The invention provides a chicken infectious laryngotracheitis subunit vaccine and application thereof, and belongs to the technical field of vaccine preparation. The chicken infectious laryngotracheitis subunit vaccine provided by the invention is prepared from chicken infectious laryngotracheitis virus gB-A463P protein coded by a gB-A463P gene of which the 463th alanine of an optimized chicken infectious laryngotracheitis gB gene is further mutated into proline, and the amino acid sequence of the gB-A463P protein is shown as SEQ ID NO: 5. The subunit vaccine is prepared by adopting a genetic engineering means, only contains part of antigens of the ILTV and does not contain genetic materials, so that the risks of toxin expelling and toxin dispersing do not exist, and the safety can be effectively improved.
Owner:YEBIO BIOENG OF QINGDAO

Preparation method of tumor microenvironment response type nano drug delivery system

The invention relates to a preparation method of a tumor microenvironment response type nano drug delivery system, which comprises the following steps: forming MnO2 nanoclusters through biomineralization induction under an alkaline condition, modifying HSA nanoparticles, then loading Ce6 through a carbodiimide method, and finally combining with a PD-L1 antibody by adopting a copper-free click chemistry method to obtain nanoparticles HMC and anti-PD-L1. The nanoparticle can be retained in a tumor tissue in a passive targeting manner through an EPR effect, and is decomposed into Mn < 2 + >, O2 and a small molecule drug through a high H2O2 and low pH microenvironment of the tumor tissue, so that the tumor permeability is greatly enhanced, the tumor immunogenicity is enhanced by combining sonodynamic therapy, the release of a tumor specific antigen and the aging of antigen presenting cells are promoted, and the tumor treatment effect is enhanced. The infiltration of tumor T cells is increased, and cold tumors are changed into hot tumors; the nanoparticles can generate O2 in situ at the same time, and the immunosuppressive ability and drug resistance caused by tumor hypoxia are overcome.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Recombinant gene of rabies virus G protein virus-like particle, virus-like particle as well as construction method and application of virus-like particle

ActiveCN119040351Astimulate immune responseIncrease secreted expressionInactivation/attenuationMicroorganism based processesNucleotideVirus Protein
The invention relates to a recombinant gene of a rabies virus G protein virus-like particle, the virus-like particle as well as a construction method and application of the virus-like particle. The nucleotide sequence of the recombinant gene is as shown in SEQ ID NO: 1. Based on a lentivirus expression system, rabies virus envelope protein is optimally designed, a transmembrane structure of the rabies virus envelope protein is replaced with a transmembrane structure of GP5 protein of the porcine reproductive and respiratory syndrome virus, and the prepared virus-like particle only contains single fragment G protein capable of generating a neutralizing antibody besides the biological characteristics of natural rabies virus, is safe and effective, has high immunogenicity, and can be used for preparing a recombinant virus. And the prepared virus-like particles are high in secretory expression quantity and can be used as candidate vaccines of novel virus rabies virus vaccines.
Owner:SOUTH CHINA INSTITUDE OF BIOMEDICINE

Cat hair allergy recombinant fusion protein as well as preparation method and application thereof

PendingCN119119294AGood immune effectreduce allergic reactionsEgg immunoglobulinsBacteriaEscherichia coliAllergy protein
The invention belongs to the technical field of bioengineering, and particularly relates to a cat hair allergy recombinant fusion protein as well as a preparation method and application thereof. The method comprises the following steps: analyzing and screening B cell epitopes of the cat hair allergic protein, carrying out series fusion expression on Feld1, Feld3, Feld4, Feld7 and Feld8 and the B cell epitopes of the allergic protein, optimizing escherichia coli codons, and realizing high-efficiency expression in an escherichia coli expression system; the fusion expression scheme not only has higher protein expression, but also enhances the immunogenicity due to the connection with the own B cell epitope. A plurality of cat hair allergy recombinant fusion proteins with strong immunogenicity are adopted to carry out subcutaneous immunization on laying hens to obtain corresponding high-titer broad-spectrum egg yolk antibodies, allergy proteins can be effectively neutralized, the egg yolk antibodies are used for preparing functional cat food or additives, and allergic reactions of animals and contact personnel can be reduced.
Owner:GUANGZHOU YUANBO MEDICAL TECH CO LTD +1

Novel chimeric flagellin and application thereof

The invention provides a novel chimeric flagellin and application thereof. The novel chimeric flagellin is formed by chimeric combination of a Senecavirus A VP2 fragment and an escherichia coli Nissle 1917 flagellin FliC through Linker (GGGGS) 3, soluble expression of the novel chimeric flagellin in an escherichia coli system is achieved, and the highest yield can reach 200 mg / L. In addition, through detection of in-vitro Caco2 and Raw264.7 cell models, the recombinant novel chimeric flagellin shows good TLR5 receptor activity, and can effectively activate a TLR5 signal channel.
Owner:LANZHOU UNIV

Preparation of exosome and electrostatic spinning composite material for promoting bone regeneration and application of exosome and electrostatic spinning composite material in bone tissue regeneration

The invention relates to the technical field of tissue engineering, and particularly discloses preparation of an exosome and electrostatic spinning composite material for promoting bone regeneration and application of the exosome and electrostatic spinning composite material in bone tissue regeneration. Identifying the multiplication capacity, the surface marker and the multidirectional differentiation capacity of the cells after the cells are separated and cultured, and finally extracting and identifying the exosome; pLLA and gelatin are dissolved in a cosolvent trifluoroethanol, composite fibers are prepared through electrostatic spinning, and a composite fiber membrane is obtained through spinning by adopting a receiver; the exosome is loaded on the surface of the PLLA / gelatin composite fiber membrane. According to the invention, the exosome derived from human mesenchymal stem cells is combined with the membrane material to prepare the exosome capable of stably releasing, the good stability and low immunogenicity of the exosome are exerted, and the effect of accurately promoting local bone regeneration is realized. And defect repair and functional reconstruction are realized.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL +1

Neural fiber light chain targeting antibody as well as preparation method and application thereof

The invention discloses an antibody targeting a nerve cellosilk light chain as well as a preparation method and application of the antibody. According to the present invention, with the HEAD structure, the prokaryotic recombinant nerve fiber filament light chain antigen has strong immunogenicity, more dominant epitopes are exposed, and the monoclonal antibody with high affinity is prepared through immunization; besides, the HEAD structural domain is fused with the specific label on the carrier, so that the stability of the antigen is greatly improved, the problem of polysinolysis caused by the property of the antigen is solved, and the success rate of antibody preparation is further improved. The antibody or the antigen binding fragment thereof can be used for early diagnosis and prognosis of neurodegenerative diseases.
Owner:BEIJING KEYGEN GENE TECH CO LTD +1

Porcine reproductive and respiratory syndrome virus NADC30 strain SCqq, inactivated vaccine and application

The invention discloses a porcine reproductive and respiratory syndrome virus NADC30 strain SCqq strain, an inactivated vaccine and application, and belongs to the technical field of veterinary medicine. The SCqq strain is preserved in the China Center for Type Culture Collection, the preservation address is Wuhan University, Wuchang District, Wuhan City, Hubei Province, the preservation number is CCTCC NO: V202486, and the preservation time is September 29, 2024. According to the invention, a porcine reproductive and respiratory syndrome virus NADC30 strain SCqq strain is screened, and an inactivated vaccine prepared from the virus strain is high in immunogenicity, safe and reliable, has a very good immune protection effect on porcine reproductive and respiratory syndrome virus NADC30 infection, can induce an organism to generate a high-level antibody, and achieves 100% virulent virus attack protection.
Owner:SICHUAN HUAPAI BIO PHARMA

Two-dimensional risedronate manganese nanobelt as well as preparation method and application thereof

The invention provides a preparation method of a two-dimensional nanobelt. The two-dimensional manganese risedronate nanobelt (RMn-NBs) is prepared from Mn < 2 + > and risedronate sodium by using a coordination self-assembly technology. The raw materials are cheap and easy to obtain, and the preparation process is simple, easy to operate and good in controllability. The two-dimensional risedronate manganese nanobelt can inhibit a hypoxia-inducible factor / vascular endothelial growth factor (HIF-1alpha / VEGF) through risedronate sodium so as to enhance the radiotherapy effect; meanwhile, Fenton-like reaction of Mn < 2 + > is utilized to amplify oxidative stress mediated by radiotherapy, a GMP-AMP synthetase stimulating factor (cGAS-STING) pathway of an interferon gene ring is synchronously activated, secretion of I-type interferon is promoted, ICD (immunogen cell death) is effectively induced, and the immunogen cell death rate is increased. And the effects of CD8 + T cell dependent systemic anti-tumor immunity and checkpoint blocking immunotherapy on primary and metastatic tumors are greatly enhanced. The RMn-NBs is used as a novel nanoscale in-situ radiotherapy vaccine, and has good biocompatibility and treatment effect.
Owner:NANJING UNIV OF POSTS & TELECOMM

Chicken infectious laryngotracheitis recombinant subunit vaccine as well as preparation method and application thereof

The invention belongs to the field of veterinary biological products, and particularly relates to a chicken infectious laryngotracheitis recombinant subunit vaccine as well as a preparation method and application thereof. A core antigen of the vaccine is a recombinant gB trimer glycoprotein (gB-Trimer) modified by genetic engineering, and the protein successfully locks a prefusion conformation with the strongest immunogenicity of the gB protein through strategies of truncation, trimerization motif splicing, dual-stability mutation and the like. The vaccine prepared by the invention can stimulate rapid and lasting neutralizing antibody response, provide 100% clinical protection and effectively block replication and detoxification of the ILTV, has extremely high biological safety compared with a traditional live vaccine, completely eliminates risks of poison dispersion and enhancement, and provides a safe and efficient novel solution for prevention and control of the ILTV.
Owner:HUAZHONG AGRI UNIV

A fusion protein capable of promoting secretion of cell membrane fixed protein, a recombinant vaccine and its application

ActiveCN118620085BIncreased level of immune responseIncrease the probability of recognizing antigensSsRNA viruses negative-senseSsRNA viruses positive-sense
The present invention relates to a vaccine framework fusion protein, a recombinant vaccine and its application. The fusion protein of the present invention comprises the intracellular segment of the low-affinity immunoglobulin gamma Fc region receptor II (FcγRII) and the WW domain (WW domain) of the E3 ubiquitin protein ligase Nedd4 family member protein, and / or one or more antigens, and / or one or more transmembrane regions. The present invention provides a new recombinant vaccine molecular architecture, which has a better ability to promote the expression and secretion of immune antigens and improve the effect of immune level, provides new ideas and methods for the design of recombinant vaccines, and can be widely used in the field of vaccines.
Owner:NANJING CHENGSHI BIOMEDICAL TECH CO LTD

Blocking ELISA kit and method for detecting Lawsonia intracellularis antibody

The invention belongs to the technical field of diagnosis of pathogenic bacteria of livestock, and particularly relates to a blocking ELISA (enzyme-linked immunosorbent assay) kit and method for detecting an intracellular Lawsonia antibody. The kit comprises an LI-OmpA recombinant antigen peptide coated ELISA plate, an enzyme-labeled antibody, a positive control, a negative control, a sample diluent, a 20-fold concentrated washing solution, a substrate developing solution and a stop solution. According to the method, an LI-OmpA recombinant antigen peptide is used as a coating antigen, an enzyme-labeled LI-OmpA recombinant antigen peptide monoclonal antibody 5F2 is used as an enzyme-labeled antibody, and the lawsonia intracellularis antibody blocking ELISA method is established. The detection method of the lawsonia intracellularis antibody blocking ELISA kit has the characteristics of high sensitivity and specificity, good repeatability and the like, and is suitable for detection of high-flux animal serum samples.
Owner:HUAZHONG AGRI UNIV

Foot and mouth disease virus effective antigen inactivation protective agent and application thereof

The invention discloses a foot and mouth disease virus effective antigen inactivation protective agent and application thereof. The protective agent is prepared from the following components in percentage by mass: 0.05 to 20 percent of a structure curing agent, 0.01 to 5 percent of an ion regulator, 0.005 to 1.0 percent of an antioxidant and the balance of water, the protective agent does not influence the inactivation effect in the process of acting on nucleic acid, inhibits folding and unfolding of a protein physical structure, prevents change of a protein space physical structure, improves free energy of protein denaturation, enhances the stability of a virus space physical structure, maintains the integrity of virions, and has a good application prospect. The effects of preserving the immune biological activity of the protein and reducing the loss of viruses in the inactivation process are achieved, so that the foot-and-mouth disease inactivation antigen liquid with high immunogenicity is obtained. Compared with the conventional antigen protection method, the method has the advantages that the virus is protected before the inactivation process is implemented, the production process is advanced, the stability of the effective antigen can be protected to the greatest extent, and support is provided for obtaining an effective antigen solution with high immunocompetence.
Owner:CHINA ANIMAL HUSBANDRY IND

Recombinant herpes zoster vaccine composition and preparation method thereof

The invention relates to the field of biological medicine, in particular to a recombinant herpes zoster vaccine composition and a preparation method thereof. The recombinant herpes zoster vaccine composition comprises gE protein and an adjuvant, the adjuvant is a squalene oil-in-water adjuvant, and the squalene oil-in-water adjuvant comprises the following components by concentration: 4-5wt% of squalene, 1-5wt% of gE protein, 1-5wt% of gE protein, 1-5wt% of gE protein, 1-5wt% of gE protein, and the balance of water. 0.2 to 0.8 wt% of Tween 80; and 0.2 to 0.8 wt% of Span 85. The vaccine composition disclosed by the invention can specifically enhance cellular immune response aiming at the varicella-zoster virus, can remarkably improve expression of cytokines such as INF-gamma and IL-2 of CD4 + T cells of mice, improves the immune response level of body fluid and cells at the same time, shows high immunocompetence for preventing clinical varicella-zoster virus infection, and has good clinical application prospects. And the components in the vaccine composition are cheap and easy to obtain, so that the vaccine yield is effectively improved, and the vaccine cost is reduced.
Owner:JIANGSU LEVIESTER BIOTECHNOLOGY CO LTD +1